Nonfacial Use of Injectable Poly-L-lactic Acid: Safety Data From a Multicenter Observational Study in the United States
Aesthetic Surgery Journal Open Forum · 14.01.2026 · 8
DOI: 10.1093/asjof/ojag053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aesthetic Surgery Journal Open Forum, online erschienen am 25.03.2026. Verfasst von Kalpna Kay Durairaj und 12 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Galderma.
Abstract (Originalsprache)
Background
Poly-L-lactic acid (PLLA-SCA) was approved for facial aesthetic use in the USA in 2009. Nonfacial aesthetic treatment using PLLA-SCA, a collagen-stimulating injectable implant, is a frequent clinical practice, and initial studies support its safety.
Objectives
The objective of this study was to evaluate the safety of PLLA-SCA when used in nonfacial areas in real clinical practice in the USA.
Methods
In this retrospective chart review, subjects treated in a nonfacial area with ≥2 vials of PLLA-SCA in ≥2 treatment sessions were eligible. Medical charts from 9 US sites were reviewed to collect demographics, treatment details, and treatment-related adverse events (AEs). The primary endpoint was treatment-related AEs.
Results
Among the 498 subjects included, most subjects (72%) had 2 or 3 treatment sessions, with an average of 4.0 vials/treatment session. Reconstitution volumes were generally ≥10 mL/vial for all treatment areas, with 47% of treatments using volumes of 10-15 mL, and another 47% using ≥15 mL/vial. The most common treatment area was the gluteal region (buttocks or hip dip; 60.3% of sessions) and decolletage (8.2% of sessions). Most treatment-related AEs were injection related and mild or moderate in intensity. The most common AE was injection site bruising (5.0%), and AEs were mainly reported in the buttocks (4.0%) or posterior thigh (1.0%). Nodule occurrence was low (1 subject, 0.2%).
Conclusions
Poly-L-lactic acid was well tolerated in real-world use for treatment of a range of nonfacial areas, with typically larger volumes than usually used for facial treatment. Level of Evidence: 3 (Therapeutic)
Autor:innen und Institutionen
ORCID-Profile: Daniel Bråsäter
Förderung
- Galderma
Zitieren
APA
Durairaj, K. K., Vafa, A., Aguilera, S. B., Fabi, S. G., Sadick, N., Palm, M. D., Levine, J., Shridharani, S. M., Mayoral, F., Bråsäter, D., Prygova, I., Wolgast, C., & Weinberg, F. (2026). Nonfacial Use of Injectable Poly-L-lactic Acid: Safety Data From a Multicenter Observational Study in the United States. Aesthetic Surgery Journal Open Forum, 8. https://doi.org/10.1093/asjof/ojag053
Vancouver
Durairaj KK, Vafa A, Aguilera SB, Fabi SG, Sadick N, Palm MD, et al. Nonfacial Use of Injectable Poly-L-lactic Acid: Safety Data From a Multicenter Observational Study in the United States. Aesthetic Surgery Journal Open Forum. 2026;8. doi:10.1093/asjof/ojag053
BibTeX
@article{Durairaj2026,
author = {Durairaj, Kalpna Kay and Vafa, Ali and Aguilera, Shino Bay and Fabi, Sabrina G and Sadick, Neil and Palm, Melanie D and Levine, Jennifer and Shridharani, Sachin M and Mayoral, Flor and Bråsäter, Daniel and Prygova, Inna and Wolgast, Charlotta and Weinberg, Felipe},
title = {Nonfacial Use of Injectable Poly-L-lactic Acid: Safety Data From a Multicenter Observational Study in the United States},
journal = {Aesthetic Surgery Journal Open Forum},
year = {2026},
volume = {8},
doi = {10.1093/asjof/ojag053}
}
EUVIMED